$81.87-1.53 (-1.83%)
CAVA Group, Inc.
CAVA Group, Inc. in the Consumer Cyclical sector is trading at $81.87 with a market capitalization of $10.4B. Wall Street consensus targets $92.00 (24 analysts), implying a +12.4% move over the next 12 months. The stock is currently 17% below its 52-week high of $98.79, remaining 16.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $438.27M↑ | $274.99M↓ | $292.24M↑ | $280.62M |
| Gross Profit | — | $111.19M↑ | $59.36M↓ | $72.37M↓ | $74.68M |
| Operating Income | — | $34.14M↑ | $8.43M↓ | $23.24M↓ | $25.82M |
| Net Income | — | $23.57M↑ | $4.92M↓ | $14.75M↓ | $18.37M |
CAVA Group, Inc. owns and operates a chain of restaurants under the CAVA brand in the United States. It also offers dips, spreads, and dressings through grocery stores. In addition, the company provides walk-the-line, online, and mobile ordering plat...
CAVA posts double-digit revenue growth and positive net income, while Krispy Kreme pursues a turnaround amid losses and a capital-light shift.
In the latest trading session, Cava Group (CAVA) closed at $83.3, marking a +1.29% move from the previous day.
Wendy's (WEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
CAVA stock jumps 37% in six months on strong traffic, expansion and raised guidance, but margin pressures and valuation warrant caution.
CAVA Group’s recent momentum in traffic growth, menu expansion and new restaurant openings has been tested by a sector-wide pullback across restaurant stocks in late June 2026, reflecting broader industry worries rather than a company-specific setback. Despite these crosscurrents, CAVA’s record past-year revenue above US$1.00 billion and continued health-focused, experience-led positioning underline how company fundamentals can diverge from short-term sector sentiment. We’ll now examine how...